# OnCo record neratinib-diarrhoea-prophylaxis-and-dose-escalation (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/neratinib-diarrhoea-prophylaxis-and-dose-escalation/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "neratinib-diarrhoea-prophylaxis-and-dose-escalation" ;
  schema:name "Neratinib: diarrhoea prevention with loperamide or dose escalation"@en ;
  schema:alternateName "neratinib diarrhoea prophylaxis"@en, "Nerlynx loperamide schedule"@en, "neratinib dose escalation"@en, "CONTROL trial strategies"@en ;
  schema:description "Neratinib, a tablet for HER2-positive breast cancer, causes diarrhoea in almost everyone. Prevent it in one of two ways agreed before you start: loperamide on a fixed schedule from the first tablet for eight weeks, or a lower starting dose built up over two weeks. Drink about two litres a day, and call your team at once if diarrhoea is severe or comes with weakness, dizziness or fever."@en ;
  schema:url <https://onco.cc/protocols/neratinib-diarrhoea-prophylaxis-and-dose-escalation/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "diarrhoea", "supportive-care" ;
  onco:related <https://onco.cc/protocols/treatment-induced-diarrhoea-grading-and-management/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/neratinib/> ;
  onco:companies <https://onco.cc/companies/puma-biotechnology/> ;
  onco:terms <https://onco.cc/terms/ctcae-grading/> ;
  onco:trials <https://onco.cc/trials/nala/> .